Uncategorized

POTOMAC, MARYLAND – March 30, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced a strategic 12-part national media partnership with

POTOMAC, MARYLAND – February 10, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Alliance Global Partners (“AGP”) has published an updated equity research report covering the Company.  The report reiterates a Buy rating and includes a price target of $3.00 per share. All statements, opinions,